Source: Healio News
The addition of isatuximab to a standard three-drug induction regimen improved outcomes for certain patients with multiple myeloma, according to randomized phase 3 study results presented at ASH Annual Meeting and Exposition.
Half of patients with transplant-eligible, newly diagnosed disease who received isatuximab (Sarclisa, Sanofi) — a CD38-directed monoclonal antibody — plus standard induction therapy with lenalidomide (Revlimid, Bristol Myers Squibb), bortezomib (Velcade, Millennium/Takeda) and dexamethasone (RVd) achieved minimal residual disease (MRD)-negative status, results